Who is the CEO of PhaseRx, Inc.?

Dr. Robert W. Overell Ph.D. is a business executive who currently serves as the CEO of PhaseRx, Inc..

What is the Revenue Growth of PhaseRx, Inc.?

Revenue growth data for PhaseRx, Inc. is currently unavailable.

What is PhaseRx, Inc. operating Margin?

PhaseRx, Inc. operating margin is 0.00% which shows how much profit PZRXQ earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does PhaseRx, Inc. operate?

PhaseRx, Inc. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is PhaseRx, Inc. revenue growth?

Revenue growth data for PhaseRx, Inc. is currently unavailable.

PhaseRx, Inc.

PZRXQ•PNK

Healthcare

Biotechnology

$0.00

$0.00(100.00%)

PhaseRx, Inc. (PZRXQ) Stock Overview

Explore PhaseRx, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for PZRXQStats details for PZRXQ are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for PZRXQAnalyst Recommendations details for PZRXQ are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell. Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency. The company was incorporated in 2006 and is headquartered in Seattle, Washington.

CEO

Dr. Robert W. Overell Ph.D.

Employees

Headquarters

410 West Harrison Street, Seattle, WA

Founded

2016